The Joint Committee on Vaccination and Immunisation (JCVI) meningococcal sub-committee is planning to convene on the 20 September 2013 via teleconference. This is in order to convene the sub-committee quickly, to maximise the availability of sub-committee members to participate and to facilitate discussion of the responses to the stakeholder consultation on the JCVI interim position statement on the use of Bexsero® meningococcal B vaccine in the United Kingdom by the members. The revised Code of Practice of the JCVI was considered and agreed by the Committee and UK health departments before publication. Both the revised and original Code of Practice were not subject to public consultation. The approach described in the report by the Working Group on Uncertainty in Vaccine Evaluation and Procurement was applied to the considerations by the JCVI and its meningococcal sub-committee about the cost effectiveness of meningococcal B immunisation programmes. The report by the Working Group on Uncertainty in Vaccine Evaluation and Procurement was considered by the Joint Committee on Vaccination and Immunisation and by the Department. The report was not subject to consultation. Those that made submissions in response to the JCVI call for evidence issued in October 2010 were: Novartis, Pfizer, the Meningitis Trust, the Meningitis Research Foundation and Meningitis UK. The study on meningococcal vaccines referred to on page 22 of the JCVI's minutes from 12 June 2013 was updated at the request of the JCVI meningococcal sub-committee to support its consideration of the impact and cost effectiveness of routine meningococcal B immunisations programmes. It was updated to take into account: the considerations of the sub-committee about inputs to, assumptions made, and sensitivity analyses in, the study based on the sub-committee's review of the evidence; to examine different immunisation strategies; to include costs for vaccine administration provided by the Department; and to support the assessment of the results of the study in line with the report by the Working Group on Uncertainty in Vaccine Evaluation and Procurement.